39 Il libro bianco sulle bronchiectasie 1. Aliberti S, Sotgiu G, Lapi F, et al. Prevalence and incidence of bronchiectasis in Italy. BMC Pulm Med. 2020;20:15. 2. Araújo D, Shteinberg M, Aliberti S, et al. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur Respir J. 2018;51:1701953. 3. Chalmers JD, Polverino E, Crichton ML, et al. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis Registry (EMBARC). Lancet Respir Med. 2023;11:637-649. 4. Choi H, Yang B, Nam H, et al. Increased mortality in patients with non cystic fibrosis bronchiectasis with respiratory comorbidities. Sci Rep. 2021;11:7126. 5. Dicker AJ, Lonergan M, Keir HR, et al. The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study. Lancet Respir Med. 2021;9:885-896. 6. Finch S, McDonnell MJ, Abo-Leyah H, et al. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann Am Thorac Soc. 2015;12:1602-1611. 7. Høyland-Kroghsbo N, Paczkowski J, et al. Quorum sensing controls the Pseudomonas aeruginosa CRISPR-Cas adaptive immune system. PNAS. 2016. 8. Huus KE, Joseph J, Zhang L, et al. Clinical Isolates of Pseudomonas aeruginosa from Chronically Infected Cystic Fibrosis Patients Fail To Activate the Inflammasome during Both Stable Infection and Pulmonary Exacerbation. J Immunol. 2016;196:3097-3108. 9. Lin J, Cheng J. Quorum Sensing in Pseudomonas aeruginosa and Its Relationship to Biofilm Development. ACS Symposium Series; American Chemical Society: Washington, DC, 2019. 10. Luo RG, Miao XY, et al. Presence of pldA and exoU in mucoid Pseudomonas aeruginosa is associated with high risk of exacerbations in non-cystic fibrosis bronchiectasis patients. Clinical Microbiology and Infection. 2019. 11. Macia MD, Blanquer D, et al. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrobial Agents and Chemotherapy. 2005. 12. Mayer-Hamblett N, Rosenfeld M, Gibson RL, et al. Pseudomonas aeruginosa In Vitro Phenotypes Distinguish Cystic Fibrosis Infection Stages and Outcomes. Am J Respir Crit Care Med. 2014;190:289-297. 13. Sin S, Yun SY, Kim JM, et al. Mortality risk and causes of death in patients with non-cystic fibrosis bronchiectasis. Respir Res. 2019;20:271. 14. Song D, Meng J, et al. Pseudomonas aeruginosa quorum-sensing metabolite induces host immune cell death through cell surface lipid domain dissolution. Nature Microbiology. 2019. 15. Sullivan E, Bensman J, et al. Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of pseudomonas aeruginosa. Critical Care Medicine. 2014. 16. Suska K, Amati F, Sotgiu G, et al. Nontuberculous mycobacteria infection and pulmonary disease in bronchiectasis. ERJ Open Res. 2022;8:00060-2022. 17. Wang R, Ding S, Lei C, Yang D, Luo H. The contribution of Pseudomonas aeruginosa infection to clinical outcomes in bronchiectasis: a prospective cohort study. Annals of Medicine. 2021;53:459-469. 18. Winstanley C, O'Brien S, Brockhurst MA. Pseudomonas aeruginosa Evolutionary Adaptation and Diversification in Cystic Fibrosis Chronic Lung Infections. Trends in Microbiology. 2016. 19. Zhou Y, Mu W, Zhang J, et al. Global prevalence of non-tuberculous mycobacteria in adults with non-cystic fibrosis bronchiectasis 2006-2021: a systematic review and meta-analysis. BMJ Open. 2022;12:e055672. Bibliografia CAPITOLO 4
RkJQdWJsaXNoZXIy MjQ4NzI=